Evidence map›Paper›PMID 27473267›Full record

ArticleHuman pathology2016

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Sarah A Weiss, Sung Won Han, Kevin Lui, Jeremy Tchack, Richard Shapiro, Russell Berman, Judy Zhong, Michelle Krogsgaard, Iman Osman, Farbod Darvishian

Erratum issuedAbstract read
In one paragraph

Article in Human pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Sarah A WeissDepartment of Medicine, New York University School of Medicine, New York, NY, USA 10016; Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016. Electronic address: Sarah.Weiss@nyumc.org.
Sung Won HanDepartment of Population Health, New York University School of Medicine, New York, NY, USA 10016. Electronic address: sungwonhan2@gmail.com.
Kevin LuiInterdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016; Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA 10016. Electronic address: kevin.paul.lui@gmail.com.
Jeremy TchackInterdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016; Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA 10016. Electronic address: Jeremy.Tchack@nyumc.org.
Richard ShapiroInterdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016; Department of Surgery, New York University School of Medicine, New York, NY, USA 10016. Electronic address: Richard.Shapiro@nyumc.org.
Russell BermanInterdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016; Department of Surgery, New York University School of Medicine, New York, NY, USA 10016. Electronic address: Russell.Berman@nyumc.org.
Judy ZhongInterdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016; Department of Biostatistics, New York University School of Medicine, New York, NY, USA 10016. Electronic address: Judy.Zhong@nyumc.org.
Michelle KrogsgaardInterdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016; Department of Pathology, New York University School of Medicine, New York, NY, USA 10016. Electronic address: Michelle.Krogsgaard@nyumc.org.
Iman OsmanDepartment of Medicine, New York University School of Medicine, New York, NY, USA 10016; Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016; Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA 10016. Electronic address: Iman.Osman@nyumc.org.
Farbod DarvishianInterdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA 10016; Department of Pathology, New York University School of Medicine, New York, NY, USA 10016. Electronic address: Farbod.Darvishian@nyumc.org.

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Cutaneous Biology and Skin Disease Training ProgramT32AR064184 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ORLOW, SETH J. · 2014 to 2024
$2.1M
NCI NIH HHS P30 CA016087NIAMS NIH HHS T32 AR064184
6 · The paper itself

Abstract

Tumor-infiltrating lymphocytes (TILs) in primary melanomas are thought to represent the host antitumor immune response, but controversy exists over whether TILs offer independent prognostication of survival. We studied a cohort of 1241 patients with primary melanoma to assess the association of absent, nonbrisk, and brisk TIL grade with survival outcomes. We tested whether quantitative TIL counts using immunohistochemical lymphocyte markers CD3, CD45, and FOXP3 add prognostic value to TIL grading compared with histology alone in 15% of the cohort. To assess for intergroup immunologic heterogeneity among TIL grades, we investigated differential expression of 594 immunoregulatory genes in 67 primary melanomas. On histologic evaluation of 1241 primary melanomas, TILs were graded as absent (n=388, 31%), nonbrisk (n=330, 27%), and brisk (n=523, 42%). Patients with brisk TILs had improved recurrence-free survival (P=.025) and overall survival (P=.006) compared with patients with nonbrisk and absent TILs, for which there were no differences in recurrence-free survival (P=.40) or overall survival (P=.41). TIL quantitation by immunohistochemistry did not improve prognostication compared with TIL grading on hematoxylin and eosin-stained sections. Melanomas with nonbrisk and absent TILs share similar immunoregulatory gene expression profiles. In contrast, melanomas with brisk TILs demonstrate upregulation of T-cell activation pathways and inhibition of upstream immune checkpoint regulators. The presence of TILs in primary melanomas represents a heterogeneous group, and caution in prognostic interpretation is warranted. Melanomas with brisk TILs are defined by an immunostimulatory gene expression profile and improved prognosis compared with melanomas with nonbrisk or absent TILs.

Indexed as

AgedBiomarkers, TumorCD3 ComplexDisease-Free SurvivalFemaleForkhead Transcription FactorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLeukocyte Common AntigensLymphocytes, Tumor-InfiltratingMaleMelanomaNeoplasm GradingBiomarkers, TumorCD3 ComplexForkhead Transcription FactorsFOXP3 protein, humanLeukocyte Common AntigensPTPRC protein, humanBriskHost immune responseMelanomaPrognosisTumor-infiltrating lymphocytes

Identifiers

PMID27473267
PMCPMC5706446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.